Strategic alliance between Quibim and Feedback Plc to improve prostate biopsy
From the Spanish medical website Tu hospital investiga para ti The Spin-Off of the IIS La Fe, Quibim has established a strategic alliance with UK company Feedback Plc to develop Prostate Checker, a tool that will improve the diagnosis of prostate cancer. Feedback Plc acquired last year TexRAD company dedicated to the analysis of tumor from medical […]
Feedback Plc – Presentation of Study Results
Feedback Plc – Presentation of Study Results On July 20th 2015, Feedback plc announced the successful completion of a large evaluation of TexRAD CT texture analysis (CTTA) as a pre-therapy imaging biomarker in 241 metastatic renal (kidney) cell cancer (m-RCC) patients treated with anti-angiogenic therapy (AAT – drugs that block cancer blood-vessel growth). The research […]
Feedback (FDBK) – Strategy update
Feedback plc (FDBK) is pleased to announce an update on its corporate strategy. Feedback has recently announced two joint ventures where its TexRAD texture analysis software is to be incorporated into developing new products designed specifically for the assessment and management of patients with prostate cancer and kidney stones. In the light of these exciting […]
Feedback PLC – NHS England “Alert” on potential application of TexRAD for assessing lung cancer patients
Feedback plc is pleased to announce that the research arm of NHS England has published an “Alert” on the potential application of Feedback’s TexRAD CT texture analysis software for assessing patients with lung cancer. The National Institute for Health Research through its Horizon Scanning Research and Intelligence Centre (NIHR HSRIC) based at the University of […]
Feedback PLC forms JV with Quibim SL to develop Prostate Checker TexRAD application
Feedback plc is pleased to announce the incorporation of a 50:50 joint venture company, Prostate Checker Ltd, with QUIBIM S.L., to develop a specific application of TexRAD texture analysis in combination with multiple extracted parameters from MR images for the computer assisted detection and diagnosis of prostate cancer. To facilitate this, Feedback Plc has granted […]
Feedback PLC announces it has licensed TexRAD to Stone Checker
Feedback plc (FDBK), the medical imaging software company, previously announced on 13 April 2015 that it had signed a research agreement with the Oxford Stone Group at the University of Oxford & Oxford University Hospital NHS Trust, UK to investigate the potential future clinical application of Feedback’s TexRAD texture analysis software on computed tomography (CT) […]
Feedback (FDBK) – First sale of TexRAD in China
Feedback plc (FDBK), the medical imaging software company, is pleased to announce the first sale for research purposes of Feedback’s TexRAD texture analysis software in China. Peking Union Medical College Hospital, Beijing, China (‘PUMCH’), has recently purchased the TexRAD software to undertake research studies in cancer and other diseases. This has been made possible via […]
Feedback PLC (FDBK) – Total voting rights
Feedback plc announces in accordance with the FCA’s Disclosure and Transparency Rules that the issued share capital of the Company comprises 203,673,857 ordinary shares. Shareholders should use 203,673,857 as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, […]
Feedback PLC (FDBK) – Study update
Feedback plc (FDBK), the medical imaging software company, is pleased to announce the successful completion of a large evaluation of TexRAD CT texture analysis (CTTA) as a pre-therapy imaging biomarker in 241 metastatic renal (kidney) cell cancer (m-RCC) patients treated with anti-angiogenic therapy (AAT – drugs that block cancer blood-vessel growth). This research study was […]
Feedback PLC – Dr Balaji Ganeshan interviewed by Justin Waite on the ADVFN podcast
Feedback PLC – Chief Scientist & News Business Officer Dr Balaji Ganeshan is interviewed by Justin Waite on the ADVFN podcast. The interview can be found 20 minutes & 30 seconds into the podcast, click here to listen to the podcast.